The Emerging Biotech Leader
by SSI Strategy
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Weekly cadence·61 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
Flexible Leadership in Biotech: Building Teams Around Program Needs
Jul 9, 2026
31m 26s
Designing Studies that Work in Complex Settings
May 22, 2026
18m 55s
Rethinking Trial Design for Rare Diseases
May 8, 2026
36m 39s
Driving Global Patient Access: Managed Access as a Strategic Lever
Feb 4, 2026
22m 17s
Rare Disease Commercialization: Beyond Approval
Jan 14, 2026
31m 55s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/9/26 | leadershipbiotech+3 | Chris Kennedy | Pacific Genetech | — | biotech leadershipteam dynamics+3 | — | 31m 26s | ||
| 5/22/26 | rare diseasestudy design+4 | Brendan Slagle | SSI Strategy | — | rare diseasestudy design+7 | — | 18m 55s | ||
| 5/8/26 | rare diseasestrial design+3 | Marshall Summar | Uncommon Cures | — | rare disease trialsclinical trial design+3 | — | 36m 39s | ||
| 2/4/26 | patient accessmanaged access+3 | Nicky Wisener | Clinigen Group | — | managed accesspatient access+5 | — | 22m 17s | ||
| 1/14/26 | rare disease commercializationpatient access+5 | Matt Trudeau | ITF TherapeuticsGenzyme+2 | — | rare diseasecommercialization+8 | — | 31m 55s | ||
| 12/2/25 | clinical operationsstrategic planning+4 | Meaghan Powers | SSI Strategy | — | clinical operationsstrategic value+6 | — | 20m 59s | ||
| 11/20/25 | clinical operationsbiotech strategy+4 | Sharon Arnold | SSI Strategy | — | clinical operationsbiotech+5 | — | 46m 08s | ||
| 11/10/25 | leadershipbiotech+3 | — | The Emerging Biotech Leader | — | biotechleadership+3 | — | 36m 28s | ||
| 11/6/25 | biotech leadershipCEO-CMO dynamic+4 | Kim KushnerAdriana Valenciano | SSI Strategy | — | biotechleadership+6 | — | 24m 03s | ||
| 10/9/25 | Chief Medical Officerbiotech leadership+5 | Dr. Ed Tucker | SSI Strategy | — | biotechCMO+8 | — | 38m 32s | ||
| 9/11/25 | biotech leadershipdevelopment stages+3 | Dr. Benit Maru | SSI Strategy | — | biotechleadership+5 | — | 25m 29s | ||
| 8/28/25 | biotech leadershipclinical programs+4 | Dr. Michael Goldstein | The Emerging Biotech LeaderSSI Strategy | IND | biotech strategyCMO role+5 | — | 46m 28s |
Showing 12 of 12
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.